Schedule 13D ownership disclosure
Spero Therapeutics Inc
Security class unavailable · CUSIP: 84833T103
Event date: 2022-11-07
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 9,190,606
- Percent of class
- 19.9900%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001387131-22-011406
- Form type
- SC 13D
- Filer
- GSK plc
- CIK
- CIK 1131399
- Filed
- Nov 14, 2022
- Reporting period
- Nov 07, 2022
- Description
- Schedule 13D beneficial ownership